MOSCOW (Reuters) – Russia will complete early-stage trials on a second potential COVID-19 vaccine produced by the Vector Institute on Sept. 30, the RIA news agency cited Russia’s consumer health safety watchdog as saying on Monday.
(Reporting by Anton Kolodyzahnyy; writing by Tom Balmforth; editing by Mark Trevelyan)
